about
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a GruppPre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study).Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Primary plasma cell leukemia in the era of new drugs: has something changed?Ixazomib for the treatment of multiple myeloma.Oral ixazomib maintenance therapy in multiple myeloma.Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study.18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders.Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres.A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma.Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.Autologous transplantation and maintenance therapy in multiple myeloma.Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.
P50
Q30595175-36976381-8051-4F9B-9F03-4D9DC3620E46Q30756778-EFE7A4EB-3AED-40A5-94B1-BE8BCD4E2682Q30802505-887B7281-C663-4B91-85C2-7638183C2574Q30828090-E407197F-C86D-447C-BF2D-855FE2767F39Q33343492-7A3EA1FD-73F9-41E5-8060-0F145366A251Q33387698-D9713F8B-93A6-41A1-A632-009452852871Q33388898-9310F721-71B0-4993-9A17-B18EE6027B4DQ33399706-24625CE3-9DEB-4489-AEE1-68B54C8C9204Q33411708-5EC0A96A-91FF-450E-A83A-CEEFB498AEDEQ33412804-3B24163B-4234-4298-843A-5C6B32037117Q33418098-04F7F7D3-E817-433C-AC36-23A5559BED67Q33428423-B0B5CECF-035D-43D9-807D-174DF93D991FQ33433893-00FD5E54-2019-4424-AFAB-78CF2442BF1BQ34479418-5B85C46E-87DA-4E33-8CED-50688F739E1FQ35220639-20B21E19-B1B4-4BC1-B49D-3666201307FFQ35588325-5F194FF1-1B4F-4750-810F-ABA52F7E9CA9Q36715906-01DFFD69-F1AC-48A4-8CDC-613C2717F1D7Q36839385-57A39AC6-F1CD-49AC-AC08-6C7B4623E9DBQ36962747-2B37A04E-0745-4EE1-AC8C-A8331F643E38Q36989576-56ED6CD7-5E6A-415E-BE1E-084B1102A5A0Q37804592-CE12F599-FF4E-4A0B-B9AD-E7EEFBC872C6Q37862262-872E74A3-BF05-4369-99D9-46ADAF3A7780Q37896333-5457D1D2-D1AE-4C3A-A198-52AABE20EB8DQ38542172-EDA5B6F7-8D75-4BD4-8AB7-75AD8264F4A1Q38640514-15F372F3-57CB-4B0E-AF78-503B38283117Q38797546-34E32225-44E2-4F50-8A8B-212D848E9939Q39070193-D94E6BA2-4E80-451C-BACF-DC8A703FF219Q39071875-3A18A286-D38A-4A85-817F-5446A03C00EAQ39430844-9E734128-E219-40C8-B831-DEF281FA332DQ39705915-4EE588C0-7BAA-454F-83C4-24EA5B84933BQ40211698-DACBACA3-21C0-460F-B31A-8164EBAA681BQ40404841-9A3DF155-0780-4BE2-B197-4603317E3573Q40454277-3EBD3A9C-A5BE-4F50-8AE9-A3CD05C45848Q40528386-8F7B3A77-3ABA-4ED6-BC0D-91455020CCAAQ40583859-86FFCB35-8BBB-4A0C-9730-F92A02E60947Q40783660-CBA7602B-DD63-475B-8D1B-D1572A266C72Q40845878-940E056B-AE6B-46F0-AE01-80D3AEAF0BDEQ40899348-B8941427-2F38-4FAA-9D58-7B8F4780A877Q41756278-9C2BAFE5-147A-42D0-BA4C-A3CA1DF104F5Q42314593-EC951537-430E-4D79-9EF1-69616265C3BF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Massimo Offidani
@ast
Massimo Offidani
@en
Massimo Offidani
@es
Massimo Offidani
@nl
Massimo Offidani
@sl
type
label
Massimo Offidani
@ast
Massimo Offidani
@en
Massimo Offidani
@es
Massimo Offidani
@nl
Massimo Offidani
@sl
prefLabel
Massimo Offidani
@ast
Massimo Offidani
@en
Massimo Offidani
@es
Massimo Offidani
@nl
Massimo Offidani
@sl
P106
P1153
56371583300
P21
P31
P496
0000-0003-2749-7347